GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Wednesday, 28 Jan 2015 | 6:07 PM ET

    Amgen Inc. fell $4.25 or 2.7 percent, to $154.64. Biogen Idec fell $6.71 or 1.9 percent, to $351.18. Celgene Corp. fell $3.39 or 2.8 percent, to $118.97.

  • Correction: Earns-Amgen story Wednesday, 28 Jan 2015 | 3:37 PM ET

    In a story Jan. 27 about drugmaker Amgen's quarterly results, The Associated Press misspelled the name of a drug and misstated the type of cancer another drug treats. Amgen tops Street 4 Q forecasts. Amgen beats 4 Q net income and revenue expectations.

  • Midday Glance: Biotechnology companies Wednesday, 28 Jan 2015 | 1:21 PM ET

    Amgen Inc. fell $2.09 or 1.3 percent, to $156.80. Biogen Idec fell $1.77 or. 5 percent, to $356.12. Celgene Corp. fell $1.71 or 1.4 percent, to $120.65.

  • Early Glance: Biotechnology companies Wednesday, 28 Jan 2015 | 10:41 AM ET

    Amgen Inc. fell$. 60 or. 4 percent, to $158.29. Biogen Idec fell$. 64 or. 2 percent, to $357.25. Celgene Corp. fell$. 13 or. 1 percent, to $122.23.

  • Final Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 6:08 PM ET

    Amgen Inc. fell$. 84 or. 5 percent, to $158.89. Biogen Idec fell $4.55 or 1.3 percent, to $357.89. Celgene Corp. fell $1.76 or 1.4 percent, to $122.36.

  • Jan 27- Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit, driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel and a tax credit. Despite pressure on overseas sales from the strong dollar that has put a crimp in pharmaceutical company profits, Amgen reiterated the 2015 forecast it provided in October for...

  • Amgen tops Street 4Q forecasts Tuesday, 27 Jan 2015 | 4:39 PM ET

    Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit. Amgen, based in Thousand Oaks, California, on Tuesday reported net income of $1.3 billion, or $1.68 per share, up from $1.02 billion, or $1.33 per share, a year earlier.

  • Jan 27- Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit, driven by strong sales of its blockbuster rheumatoid arthritis drug Enbrel, cost cutting and a tax credit. The world's largest biotechnology company posted a net profit of $1.29 billion, or $1.68 per share, compared with a profit of $1.02 billion, or $1.33 per share, a year ago.

  • Midday Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 1:36 PM ET

    Amgen Inc. fell$. 17 or. 1 percent, to $159.57. Biogen Idec fell $2.29 or. 6 percent, to $360.15. Celgene Corp. fell$. 81 or. 7 percent, to $123.31.

  • Early Glance: Biotechnology companies Tuesday, 27 Jan 2015 | 10:25 AM ET

    Amgen Inc. fell$. 82 or. 5 percent, to $158.91. Biogen Idec rose$. 02 or percent, to $362.46. Celgene Corp. fell$. 68 or. 5 percent, to $123.44.

  • Final Glance: Biotechnology companies Monday, 26 Jan 2015 | 6:04 PM ET

    Amgen Inc. fell$. 08 or. 1 percent, to $159.73. Biogen Idec rose $4.91 or 1.4 percent, to $362.44. Celgene Corp. rose$. 23 or. 2 percent, to $124.12.

  • Midday Glance: Biotechnology companies Monday, 26 Jan 2015 | 1:53 PM ET

    Amgen Inc. rose$. 26 or. 2 percent, to $160.07. Biogen Idec rose $3.25 or. 9 percent, to $360.78. Celgene Corp. rose$. 16 or. 1 percent, to $124.05.

  • Early Glance: Biotechnology companies Monday, 26 Jan 2015 | 12:16 PM ET

    Amgen Inc. fell$. 98 or. 6 percent, to $158.83. Biogen Idec fell$. 29 or. 1 percent, to $357.24. Celgene Corp. fell$. 56 or. 5 percent, to $123.33.

  • NEW YORK, Jan 26- A new wave of experimental cancer drugs that directly recruit the immune system's powerful T cells are proving to be immensely effective weapons against tumors, potentially transforming the $100 billion global market for drugs that fight the disease. But top oncology researchers are concerned about the two emerging technologies, citing...

  • Final Glance: Biotechnology companies Friday, 23 Jan 2015 | 6:04 PM ET

    Amgen Inc. rose$. 24 or. 2 percent, to $159.81. Biogen Idec rose $3.88 or 1.1 percent, to $357.53. Celgene Corp. rose$. 18 or. 1 percent, to $123.89.

  • Midday Glance: Biotechnology companies Friday, 23 Jan 2015 | 1:31 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $159.12. Biogen Idec rose $4.60 or 1.3 percent, to $358.25. Celgene Corp. rose$. 04 or percent, to $123.75.

  • Early Glance: Biotechnology companies Friday, 23 Jan 2015 | 11:24 AM ET

    Amgen Inc. fell$. 51 or. 3 percent, to $159.07. Biogen Idec rose $2.25 or. 6 percent, to $355.90. Celgene Corp. fell$. 73 or. 6 percent, to $122.98.

  • Final Glance: Biotechnology companies Thursday, 22 Jan 2015 | 6:05 PM ET

    Amgen Inc. rose $2.19 or 1.4 percent, to $159.57. Biogen Idec fell $8.18 or 2.3 percent, to $353.65. Celgene Corp. rose $1.49 or 1.2 percent, to $123.71.

  • Midday Glance: Biotechnology companies Thursday, 22 Jan 2015 | 1:29 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $157.80. Biogen Idec fell $10.37 or 2.9 percent, to $351.46. Celgene Corp. fell$. 20 or. 2 percent, to $122.02.

  • This measure says stocks are really cheap…maybe Thursday, 22 Jan 2015 | 12:26 PM ET
    Traders on the floor of the New York Stock Exchange.

    One valuation measure has sparked a debate among strategists as to whether the stock market is really, really cheap.